Other Information.
−Removed: Pursuant to the terms of the License Agreement dated November 4, 2018 between the Company and Abeona Therapeutics Inc.
−Removed: (Abeona), as amended on November 4, 2019 (the License Agreement), Abeona was required to make a payment of $8.0 million to us no later than April 1, 2020.
−Removed: Abeona failed to make this payment and we therefore delivered to Abeona a written demand for payment and breach notice in April 2020.
−Removed: Upon expiration of the applicable cure period under the License Agreement, which expiration occurred on May 2, 2020, the License Agreement was terminated.
−Removed: Upon termination , all rights and licenses granted to Abeona under the License Agreement terminated and an additional $20.0 million fee that would have otherwise been due to us in November 2020 will become payable within 15 days of the termination date.
−Removed: A summary of the material terms and conditions of the License Agreement is set forth in our Current Report on Form 8-K filed with the U.S.
−Removed: Securities and Exchange Commission (the SEC) on November 6, 2018.
−Removed: The License Agreement is filed as Exhibit 10.22 to our Annual Report on Form 10-K filed with the SEC on February 27, 2019, and the First Amendment to the License Agreement dated November 4, 2019 is filed as Exhibit 10.23 to our Annual Report on Form 10-K filed with the SEC on February 26, 2020.
−Removed: The description of the terms and conditions of the License Agreement contained in this Quarterly Report on Form 10-Q and the summary contained in the Current Report on Form 8-K referenced above do not purport to be complete and are qualified in their entirety by reference to the full text of the License Agreement.
Incorporated by Reference
4 unchanged sentences
Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C.
−Removed: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020 formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets
3 unchanged sentences
(v) Notes to Consolidated Financial Statements
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020 formatted in Inline XBRL (included in Exhibit 101)
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2020 formatted in Inline XBRL (included in Exhibit 101)
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of REGENXBIO Inc.
2 unchanged sentences
REGENXBIO Inc.
+Added: August 6, 2020
/s/ Kenneth T.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 6, 2020
/s/ Vittal Vasista
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.